Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug shield Teens' kidneys?

NCT ID NCT07405216

Disease control Sponsor: Centenario Hospital Miguel Hidalgo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether dapagliflozin, a drug already used in adults to protect kidneys, can reduce protein leakage in the urine of teenagers with mild chronic kidney disease. Two hundred adolescents aged 14 to 18 will receive either the drug or a placebo for six months. The goal is to see if the drug slows kidney damage and is safe for this age group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dapagliflozin (a diabetes drug that protects kidneys)
What this could lead to
If it works, this could provide a new treatment to slow kidney disease in teenagers, reducing the risk of kidney failure later in life.
What could go wrong
This is a small, early-phase trial in a specific population, so results may not apply broadly. The drug may not reduce protein in urine or could cause side effects like dehydration or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

14 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:Age 14-18 years Residence in Aguascalientes Persistent albuminuria (ACR \>30 and \<300 mg/g) Estimated glomerular filtration rate ≥60 mL/min/1.73 m² No identifiable secondary cause (e.g., lupus, diabetes mellitus) Renal biopsy showing adaptive podocytopathy or perihilar focal segmental glomerulosclerosis - Exclusion Criteria: Hypoalbuminemia Nephrotic syndrome Persistent macroalbuminuria (ACR \>300 mg/g) Secondary causes of CKD, including congenital anomalies of the kidney and urinary tract or polycystic kidney disease -

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adolescent are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Albuminuria chronic kidney disease chronic renal failure syndrome proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adolescent Albuminuria Chronic kidney disease (mild to moderate) Sodium glucose co-transporter 2 inhibitors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Instituto de atención Integral de Enfermedades Renales del Estado de Aguascalientes

    RECRUITING

    Aguascalientes, Aguascalientes, 20000, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.